Potent HCV NS3 Protease Inhibition by a Water-Soluble Phyllanthin Congener

被引:3
|
作者
Reddy, Uma B. [2 ]
Tandon, Himani [1 ]
Pradhan, Manoj K. [4 ]
Adhikesavan, Harikrishnan [4 ]
Srinivasan, Narayanaswamy [1 ]
Das, Saumitra [2 ,3 ]
Jayaraman, Narayanaswamy [4 ]
机构
[1] Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India
[2] Indian Inst Sci, Microbiol & Cell Biol, Bangalore 560012, Karnataka, India
[3] Natl Inst Biomed Genom, Kalyani 741251, W Bengal, India
[4] Indian Inst Sci, Dept Organ Chem, Bangalore 560012, Karnataka, India
来源
ACS OMEGA | 2020年 / 5卷 / 20期
关键词
HEPATITIS-C-VIRUS; CRYSTAL-STRUCTURES; SERINE-PROTEASE; RNA REPLICATION; AMARUS; PROTEINASE; RESISTANCE; CLEAVAGE; FITNESS; ASSAY;
D O I
10.1021/acsomega.0c00786
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
NS3/4A protease of hepatitis C virus (HCV) plays an important role in viral RNA replication. A 1,4-diphenylbutanedicarboxylic acid derivative, namely, phyllanthin, extracted from the leaf of a herbal plant, Phyllanthus amarus, inhibits HCV NS3/4A protease and replication activities. However, the reduced aqueous solubility, high toxicity, and poor oral bioavailability are major impediments with phyllanthin. We herein present a design approach to generate phyllanthin congeners in order to potentiate inhibition activity against protease. The phyllanthin congeners were synthesized by chemical methods and subjected to systematic biological studies. One of the congeners, annotated as D8, is identified as a novel and potent inhibitor of the HCV-NS3/4Aprotease activity in vitro and the viral RNA replication in cell culture. Structural analysis using the computational-based docking approach demonstrated important noncovalent interactions between D8 and the catalytic residues of the viral protease. Furthermore, D8 was found to be significantly nontoxic in cell culture. More importantly, oral administration of D8 in BALB/c mice proved its better tolerability and bioavailability, as compared to native phyllanthin. Taken together, this study reveals a promising candidate for developing anti-HCV therapeutics to control HCV-induced liver diseases.
引用
收藏
页码:11553 / 11562
页数:10
相关论文
共 50 条
  • [1] Macrocyclic inhibitors of HCV NS3 protease
    Venkatraman, Srikanth
    Njoroge, F. George
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2009, 19 (09) : 1277 - 1303
  • [2] Potent aza-peptide derived inhibitors of HCV NS3 protease
    Venkatraman, Srikanth
    Wu, Wanli
    Shih, Neng-Yang
    Njoroge, F. George
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (16) : 4760 - 4763
  • [3] Boceprevir, an NS3 Protease Inhibitor of HCV
    Berman, Kenneth
    Kwo, Paul Y.
    CLINICS IN LIVER DISEASE, 2009, 13 (03) : 429 - +
  • [4] Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease
    Li, Xianfeng
    Zhang, Yong-Kang
    Liu, Yang
    Zhang, Suoming
    Ding, Charles Z.
    Zhou, Yasheen
    Plattner, Jacob J.
    Baker, Stephen J.
    Liu, Liang
    Bu, Wei
    Kazmierski, Wieslaw M.
    Wright, Lois L.
    Smith, Gary K.
    Jarvest, Richard L.
    Duan, Maosheng
    Ji, Jing-Jing
    Cooper, Joel P.
    Tallant, Matthew D.
    Crosby, Renae M.
    Creech, Katrina
    Ni, Zhi-Jie
    Zou, Wuxin
    Wright, Jon
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (24) : 7493 - 7497
  • [5] Potent ketoamide inhibitors of HCV NS3 protease derived from quaternized P1 groups
    Venkatraman, Srikanth
    Velazquez, Francisco
    Wu, Wanli
    Blackman, Melissa
    Madison, Vincent
    Njoroge, F. George
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (07) : 2151 - 2155
  • [6] Potent novel inhibitors against hepatitis C virus NS3 (HCV NS3 GT-3a) protease domain
    Ikram, Saima
    Ahmad, Jamshaid
    Rehman, Irshad-Ur
    Durdagi, Serdar
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2020, 101
  • [7] Effect of protease and helicase mutations on HCV NS3 activity
    Eisa, Zaki Monawar
    SAUDI JOURNAL OF BIOLOGICAL SCIENCES, 2011, 18 (02) : 195 - 200
  • [8] Phylogenetic analysis, structure modeling and docking study of HCV NS3 protease for the identification of potent inhibitors
    Zia, Asad
    Abbasi, Sumra Wajid
    Ahmad, Shabeer
    Zia, Muhammad
    Raza, Abida
    INFECTION GENETICS AND EVOLUTION, 2018, 59 : 51 - 62
  • [9] Mechanistic role of NS4A and substrate in the activation of HCV NS3 protease
    Zhu, Haimei
    Briggs, James M.
    PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2011, 79 (08) : 2428 - 2443
  • [10] Design and synthesis of novel fluoro amino acids: synthons for potent macrocyclic HCV NS3 protease inhibitors
    Nair, Latha G.
    Bogen, Stephane
    Bennett, Frank
    Chen, Kevin
    Vibulbhan, Bancha
    Huang, Yuhua
    Yang, Weing
    Doll, Ronald J.
    Shih, N. -Y.
    Njoroge, F. George
    TETRAHEDRON LETTERS, 2010, 51 (23) : 3057 - 3061